Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The U.S. Food & Drug Administration has granted orphan drug designation to Chicago-based Amphix Bio's treatment for acute ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

As one FDA initiative works to sustain the momentum of rare disease research, other events threaten to slow progress.

Clinical-stage biotech stocks carry significant risks, but also offer explosive upside potential. These companies are built ...

President Donald Trump’s “big, beautiful bill,” which he signed into law earlier this month, includes major wins for business ...

BrainStorm Cell Therapeutics Inc. shares crashed 42.74% to $0.67 in after-hours trading on Friday after the company announced ...

Mesoblast's shares rallied ahead of the bell Friday after the Australian regenerative medicine company disclosed initial sales of Ryoncil, its recently launched mesenchymal stromal cell therapy for ...

INDIAN pharmaceutical company MSN Laboratories has established a wholly owned subsidiary in Jamaica, positioning the country ...

Prescient Therapeutics has signalled its position as one of the most advanced oncology companies on the ASX, according to ...

Investing.com -- Mesoblast Ltd (NASDAQ: MESO) stock surged 25% after the company reported its first quarter of sales for its newly approved drug Ryoncil, which generated $13.2 million in gross revenue ...

Brainstorm Cell Therapeutics ( ($BCLI) ) has provided an update. On July 16, 2025, BrainStorm Cell Therapeutics Inc. was notified by Nasdaq of its ...